birb 796 has been researched along with imatinib mesylate in 5 studies
| Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 137 | 5 | 80 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | birb 796 (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Druker, BJ; O'Hare, T | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Soverini, S | 1 |
| Bukhtiyarova, M; Karpusas, M; Lee, Y; Namboodiri, HV; Ramcharan, J; Springman, EB | 1 |
| Dietrich, J; Hulme, C; Hurley, LH | 1 |
| Liu, H; Shen, Y; Yang, Y; Yao, X | 1 |
5 other study(ies) available for birb 796 and imatinib mesylate
| Article | Year |
|---|---|
BIRB-796 is not an effective ABL(T315I) inhibitor.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Naphthalenes; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyrimidines | 2005 |
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Benzene Derivatives; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Naphthalenes; Panobinostat; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Structure-Activity Relationship; Threonine; Vorinostat | 2007 |
Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Topics: Benzamides; Benzenesulfonates; Crystallography, X-Ray; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship | 2010 |
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Drug Design; Hydrogen Bonding; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Naphthalenes; Niacinamide; Oligopeptides; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib | 2010 |
Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Topics: Allosteric Regulation; Benzamides; Benzenesulfonates; Catalytic Domain; Humans; Imatinib Mesylate; Indenes; Mitogen-Activated Protein Kinase 14; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Thermodynamics | 2011 |